Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Ruchi Gupta

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen (AMGN) is a biotech company based in California. It specializes in developing treatments for cardiovascular conditions, oncology, hematology, neurology, bone health, nephrology, and more.

Amgen’s stock has grown steadily this year, gaining 20% in 2025. However, shares are still trading roughly 10% below their 52-week high of $346.85. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.